ADVERTISEMENTs
Trump’s drug pricing push puts India’s pharma exports on notice
The move, analysts say, could mark a turning point in how Washington sources and prices medicines.
-
Lalit K Jha (5WH) - Fri, 10, Oct 2025
- 21:48 EDT
- 28
President Donald Trump. / Instagram/@realdonaldtrump
President Donald Trump’s sweeping drug pricing plan and AstraZeneca’s $50 billion pledge to expand U.S. manufacturing might have an adverse impact on India’s pharmaceutical industry, which supplies nearly 40 per cent of America’s generic drugs.
The plan, announced Oct. 10 at the White House, ties the cost of prescription medicines in the United States to the lowest available global rate — the so-called “Most Favoured Nation” pricing model. “Americans have paid the highest prices anywhere in the world for prescription drugs, by far,” Trump said.
ALSO READ: What does Trump's deal with Pfizer mean for drug prices?
This post is for paying subscribers only
SUBSCRIBE NOWRelated
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
E Paper
ADVERTISEMENT
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login